StreetAlpha
13F holdings · Q2 2026

Regeneron Pharmaceuticals

Tarrytown, NY · files as Regeneron Pharmaceuticals, Inc.
Holdings as of Jun 30, 2026Filed Aug 7, 2026Next filing due Nov 16, 2026CIK 872589

Regeneron Pharmaceuticals reported 3 stocks worth $177M in its 13F filing for Q2 2026, filed Aug 7, 2026. Its largest holdings are PBLS (64.3%), NTLA (35.4%) and ACET (0.3%). Compared with Q1 2026, the fund opened new positions in PBLS and ACET and sold out of ACET.

Reported value$177M+270.1% vs last quarter
Stocks held32 new · 1 sold out
Top 5 weight100.0%very concentrated
Turnover65%of the portfolio changed
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 7 qtrsHeld
1
PBLS
Parabilis Medicines Inc Com
$114M64.3%4.2MNew position1 of 7
2
NTLA
Intellia Therapeutics Inc
$62.7M35.4%3.7MNo change7 of 7
3
ACET
Adicet Bio Inc
$523K0.3%61KNew position1 of 7

Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q1 2026, gone in Q2 2026
StockValue last quarterShares sold
ACET
Adicet Bio Inc
$412K61K

Reported value

last 7 quarters
$1.1BQ4 '24
$1.2BQ1 '25
$1.5BQ2 '25
$700MQ3 '25
$33.8MQ4 '25
$47.9MQ1 '26
$177MQ2 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q2 2026

straight from the SEC
FiledFormQuarter
Aug 7, 202613F-HRQ2 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Regeneron Pharmaceuticals 13F FAQ

What does Regeneron Pharmaceuticals own?

Regeneron Pharmaceuticals reported 3 stocks worth $177M in its 13F filing for Q2 2026, filed Aug 7, 2026. Its largest holdings are PBLS (64.3%), NTLA (35.4%) and ACET (0.3%). The table above lists every position in the filing (the top 10 without an account).

What did Regeneron Pharmaceuticals buy and sell in Q2 2026?

Compared with Q1 2026: 2 new positions, 0 added to, 0 trimmed and 1 sold out. New positions include PBLS and ACET. It sold all of ACET.

When will Regeneron Pharmaceuticals file its next 13F?

Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.

How much is Regeneron Pharmaceuticals's portfolio worth?

The Q2 2026 filing reports $177M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.